Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;57(11):653-663.
doi: 10.1358/dot.2021.57.11.3319146.

Belantamab mafodotin for the treatment of multiple myeloma

B Wang  1 , C Wu  1 , Q Zhong  2 , L Ling  1 , Z Wu  3 , B Yu  1 , X Gao  1 , H Zeng  4 , D-H Yang  5
Affiliations

Belantamab mafodotin for the treatment of multiple myeloma

B Wang et al. Drugs Today (Barc). 2021 Nov.

Abstract

Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the 2000s, relapse of multiple myeloma is inevitable. Currently, the main therapeutic agents for multiple myeloma treatment include proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and others. Patients who relapse or are refractory to the above-mentioned treatments have poor prognosis. B-cell maturation antigen (BCMA) is a cell-surface receptor which is expressed on the membrane of multiple myeloma cells, but absent on naive and memory B cells, making it an ideal target for multiple myeloma treatment. Belantamab mafodotin (GSK-2857916) is a first-in-class BCMA antibody-drug conjugate with an overall response rate of 32% in the phase II clinical trial DREAMM-2, which is a phase II study designed to investigate the efficacy and safety of belantamab mafodotin in relapsed/refractory patients with multiple myeloma. In August 2020, based on the results of this pivotal DREAMM-2 study, the U.S. Food and Drug Administration (FDA) approved belantamab mafodotin as a monotherapy for relapsed/refractory multiple myeloma. Thereafter, the European Medicines Agency (EMA) also approved this indication. Although belantamab mafodotin has demonstrated single-agent activity in relapsed/refractory multiple myeloma, further studies to evaluate its efficacy and its combinational use with other drugs are necessary and ongoing.

Keywords: Anti-B-cell maturation antigen (BCMA) agents; Antibody-drug conjugates; Belantamab mafodotin; Cancer immunotherapy; Hematologic malignancies; Microtubule destabilizers; Multiple myeloma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources